Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. (IPSC) received an updated ownership filing showing that Point72 entities report beneficial ownership of 5,961,563 common shares, representing 6.8% of the company. The stake is held through Point72 Associates, LLC, with Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen reporting shared voting and investment power.
The information is stated as of the close of business on January 2, 2026 and is filed as Amendment No. 1 to correct beneficial ownership previously disclosed. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.
Century Therapeutics SVP Finance & Operations Douglas Carr reported a small automatic share sale linked to equity compensation. On February 3, 2026, he sold 323 shares of Common Stock at $1.822 per share to cover tax withholding obligations from vesting restricted stock units.
After this tax-related sale, Carr beneficially owned 514,551 shares of Century Therapeutics common stock, held directly. The filing explains that the transaction was executed automatically and was not made at his discretion.
Century Therapeutics, Inc. is registering 176,086,947 shares of common stock for resale by existing investors following a January 7, 2026 private placement. The shares include PIPE stock plus shares issuable from pre-funded and common warrants.
This is a secondary offering, so Century will not receive proceeds from any stockholder sales, though it may receive cash if warrants are exercised. Century develops off‑the‑shelf iPSC-derived cell therapies for autoimmune diseases and cancer, with lead programs CNTY‑813 for Type 1 diabetes, CNTY‑308 for B‑cell diseases, and CNTY‑101 for B‑cell‑mediated autoimmune diseases.
Century Therapeutics President and CEO Brent Pfeiffenberger received new equity awards. On February 2, 2026, he was granted 475,000 shares of common stock in the form of restricted stock units at a price of $0 per share.
He also received a stock option for 945,000 shares of common stock at an exercise price of $1.84 per share. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over three years, while the option vests 25% on February 2, 2027 and the rest in 36 equal monthly installments, all subject to continued service.
Century Therapeutics, Inc. reported that Chief Technology and Manufacturing Officer Gregory Russotti received new equity awards. On February 2, 2026, he was granted 135,000 shares of common stock in the form of restricted stock units at $0 per share, increasing his directly held common stock to 525,982 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service.
Russotti was also granted a stock option for 265,000 shares of common stock at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the balance in 36 equal monthly installments thereafter. In addition, 92,773 shares of common stock are reported as indirectly owned through the Gregory Russotti 2021 Family Trust.
Century Therapeutics Chief Scientific Officer Chad Cowan received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 135,000 restricted stock units at no cash cost, increasing his directly held common stock to 1,178,476 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service. He was also granted a stock option covering 265,000 shares of common stock at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the balance in 36 equal monthly installments, also subject to continued service. Separately, 10,697 shares are held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except for any pecuniary interest.
Century Therapeutics reported that Douglas Carr, its SVP Finance & Operations, received equity awards. He was granted 110,000 restricted stock units, each representing one share of common stock, vesting 25% on February 2, 2027 and the remaining 75% quarterly over three years, subject to continued service.
He was also granted a stock option for 225,000 shares at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the remaining 75% in 36 equal monthly installments, expiring on February 2, 2036. After these grants, he beneficially owns 514,874 common shares directly and 225,000 options.
Century Therapeutics, Inc. held a special stockholder meeting where investors approved an amendment to its charter that would allow a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-30, at the discretion of the board. The proposal received 55,089,478 votes for, 5,361,020 against, and 27,055 abstentions, indicating strong support for the potential split. On the same day, the company received notice from the Nasdaq Stock Market that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. Because the company is now in compliance with all continued listing standards, it does not intend to implement the reverse stock split that stockholders approved.
Century Therapeutics, Inc. received a Schedule 13G from RA Capital Management and related parties reporting a significant passive ownership position. RA Capital Healthcare Fund directly holds 17,754,430 shares of common stock, plus pre-funded warrants exercisable for up to 8,332,526 shares and additional warrants exercisable for up to 13,043,478 shares of common stock. A beneficial ownership blocker in these warrants limits the group’s exercisability so that total beneficial ownership does not exceed 9.99% of Century’s common stock, which is currently 17,944,649 shares.
The 9.99% figure is calculated using 87,405,311 shares outstanding as of November 25, 2025, plus 92,030,595 shares issued in a January 9, 2026 private placement and 190,219 shares issuable upon warrant exercise. RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and individuals Peter Kolchinsky and Rajeev Shah report shared voting and dispositive power over these securities and certify they are not holding them to change or influence control of Century Therapeutics.
Century Therapeutics, Inc. received a Schedule 13G from a group of Venrock-affiliated investment entities and individuals reporting a significant ownership position. The group reports beneficial ownership of 13,043,478 shares of common stock (including shares underlying warrants that are immediately exercisable for 4,347,826 shares), representing 7.1% of the common stock. The holdings are spread across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., and related management entities, with Nimish Shah and Bong Koh as voting members of the managing entities. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.